

Literatura ACTA MEDICINAE 14/2023 Vnitřní lékařství

- 2 **Kardiorenální metabolický syndrom**
prof. MUDr. Kateřina Štechová, Ph.D. Interní klinika 2. LF UK a FN v Motole
- 2 **V léčbě vysokého krevního tlaku máme stále problémy**
prof. MUDr. Miroslav Souček, CSc. II. interní klinika FN u sv. Anny v Brně a LF MU, Brno
- 2 **Perindopril s indapamidem ve fixní kombinaci k léčbě arteriální hypertenze u obézního nemocného s prediabetem – kazuistika**
prof. MUDr. Robert Holaj, CSc., MBA Centrum pro výzkum, diagnostiku a léčbu hypertenze, III. interní klinika, 1. LF UK a VFN, Praha
- 2 **Deprese a kardiovaskulární choroby v kontextu zánětlivých procesů**
MUDr. Eva Kitzlerová, Ph.D. Psychiatrická klinika 1. LF UK a VFN, Praha
- 3 **Oční projevy interních onemocnění**
doc. MUDr. Ján Lešták, CSc., MSc, MBA, LLA, DBA, FEBO, FAOG Fakulta biomedicínského inženýrství ČVUT v Praze
- 3 **Kožní změny u interních pacientů – vitiligo**
MUDr. Barbora Divišová, Ph.D. Dermafit Centrum, s. r. o., Plzeň
- 3 **Dapagliflozin v ordinaci internisty**
prof. MUDr. David Karásek, Ph.D. III. interní klinika – nefrologická, revmatologická a endokrinologická, LF UP a FN Olomouc
- 4 **Inkretiny (GIP a GLP-1) – aktuální pohled na patofyziologii a klinické perspektivy**
prof. MUDr. Jan Škrha, DrSc., MBA III. interní klinika endokrinologie a metabolismu 1. LF UK a VFN, Praha
- 4 **Infekční komplikace u syndromu diabetické nohy**
MUDr. Dominika Sojáková Centrum diabetologie IKEM a 1. LF UK, Praha MUDr. Radka Jarošíková | MUDr. Vladimíra Fejfarová, Ph.D. Centrum diabetologie IKEM a 2. LF UK, Praha MUDr. Michal Dubský, Ph.D. FRSPH Centrum diabetologie IKEM a 1. LF UK, Praha
- 4 **Léčba bolesti v interní ambulanci**
MUDr. Jan Procházka, Ph.D. Centrum léčby chronické bolesti při KAPIM, KZ, a. s., Masarykova nemocnice Ústí nad Labem
- 5 **Refluxní choroba jícnu – současný pohled**
MUDr. Tomáš Skutil | MUDr. Štefan Konečný | MUDr. Jitka Vaculová Interní gastroenterologická klinika FN a LF MU, Brno
- 5 **Idiopatické střevní záněty – farmakologická léčba, současné možnosti, výhledy**
MUDr. Hana Nováková, Ph.D. Interní gastroenterologická klinika FN Brno a LF Masarykovy univerzity, Brno
- 5 **Praktické zkušenosti s léčbou inhibitory komplementu u paroxysmální noční hemoglobinurie**
MUDr. Libor Červínek, Ph.D. Interní hematologická a onkologická klinika Fakultní nemocnice Brno
prof. MUDr. Pavel Žák, Ph.D. IV. interní hematologická klinika LF UK a FN Hradec Králové
MUDr. Jacqueline Soukupová Maaloufová Ústavu hematologie a krevní transfuze Praha
MUDr. Lenka Nosáková, PhD. | MUDr. Kristína Cmarková Klinika viscerální, všeobecné a transplantační chirurgie, Univerzitní nemocnice Martin, Jesseniova lékařská fakulta Martin, Univerzita Komenského Bratislava | MUDr. Jakub Hoferica | MUDr. Matúš Ščur | MUDr. Juraj Chudej, PhD. | doc. MUDr. Peter Bánovčin, PhD. Interní klinika gastroenterologická, Univerzitní nemocnice Martin, Jesseniova lékařská fakulta Martin, Univerzita Komenského Bratislava
- 6 **Mnohočetný myelom – jak ho nepřehlédnout – kazuistika a rychlý přehled**
MUDr. Jan Vachek, MHA Klinika nefrologie, 1. LF UK a VFN, Praha

Kardiorenální metabolický syndrom

prof. MUDr. Kateřina Štechová, Ph.D. Interní klinika 2. LF UK a FN v Motole

- 1 Akiyama, H. – Nishimura, A. – Morita, N., et al.: Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. *Front Endocrinol*, 2023, 14, doi: 10.3389/fendo.2023.1111984.
- 2 Bar-Tana, J.: mTORC1 syndrome (TorS): unified paradigm for diabetes/metabolic syndrome. *Trends Endocrinol Metab*, 2023, 34, s. 135–145.
- 3 Bez uvedení autora: Cases and observations illustrative of renal disease, accompanied with the secretion of albuminous urine. *Med Chir Rev*, 1836, 25, s. 23–35.
- 4 Dauriz, M. – Mantovani, A. – Bonapace, S., et al.: Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis. *Diabetes Care*, 2017, 40, s. 1597–1605.
- 5 Davies, M. J. – Aroda, V. R. – Collins, B. S., et al.: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, 2022, 45, s. 2753–2786.
- 6 Handelsman, Y. – Butler, J. – Bakris, G. L., et al.: Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. *J Diabetes Complications*, 2023, 37, s. 108389.
- 7 Méndez Fernández, A. B. – Vergara Arana, A. – Olivella San Emeterio, A., et al.: Cardiorenal syndrome and diabetes: an evil pairing. *Front Cardiovasc Med*, 2023, 10, s. 1185707.
- 8 Ronco, C. – Haapio, M. – House, A. A., et al.: Cardiorenal syndrome. *J Am Coll Cardiol*, 2008, 52, s. 1527–1539.
- 9 Silveira Rossi, J. L. – Barbalho, S. M. – Reverete de Araujo, R., et al.: Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. *Diabetes Metab Res Rev*, 2022, 38, s. e3502.
- 10 Salvatore, T. – Galiero, R. – Caturano, A., et al.: An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. *Int J Mol Sci*, 2022, 23, s. 3651.
- 11 Whaley-Connell, A. – Sowers, J. R.: Basic science: Pathophysiology of the cardiorenal metabolic syndrome. *J Am Soc Hypertens*, 2014, 8, s. 604–606.

V léčbě vysokého krevního tlaku máme stále problémy

prof. MUDr. Miroslav Souček, CSc. II. interní klinika FN u sv. Anny v Brně a LF MU, Brno

- 1 Williams, B. – Mancia, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for management of arterial hypertension. *Eur Heart J*, 2018; 39(10): 3021–3004.
- 2 Widimský, J. – Filipovský, J. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2017. Doporučení České společnosti pro hypertenzi. *Vnitř Lek*, 2018, 64, s. 771–796.
- 3 Souček, M. – Kára, T., et al.: *Klinická patofyziologie hypertenze*. Grada Publishing, 2002.
- 4 Williams, B. – Mancia, G. – Spiering, W., et al.: ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*, 2018, 39/33, s. 3021–3104.
- 5 Vidal-Petiot, E. – Ford, I. – Greenlaw, N., et al.: Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. *Lancet*, 2016, 388, s. 2142–2152.
- 6 Carrao, G. – Nicotra, F. – Parodi, A., et al.: Cardiovascular prevention by initial and subsequent combination of antihypertensive drugs in daily life practice. *Hypertension*, 2011, 58, s. 566–572.
- 7 Souček, M.: Výsledky průřezového průzkumu RAPID control u pacientů s hypertenzí. 2023. V tisku.
- 8 Mazzaglia, G. – Ambrosioni, E. – Alacqua, M., et al.: Adherence to antihypertensive medication and cardiovascular morbidity a mortality among newly diagnosed hypertensive patients. *Circulation*, 2009, 12, s. 1598–1605.
- 9 Štrauch, B. – Petrák, O. – Zelinka, T., et al.: Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. *J Hypertens*, 2013, 31, s. 1455–2461.
- 10 Gupta, A. K. – Patel, P. – Strauch, B., et al.: Risk factors for nonadherence to antihypertensive treatment. *Hypertension*, 2017, 69, s. 1113–1120.
- 11 Rosolová, H.: Adherence a persistence k léčbě. *Svět praktické medicíny*, 2021, 3, s. 38–40.
- 12 Van Wijk, B. L. G. – Klungel, O. H. – Heerding, E. R.: Rate and determinants of 10-year persistence with antihypertensive drug. *J Hypertens*, 2005, 23, s. 2101–2107.
- 13 Gupta, A. K. – Arshad, S. – Poulter, N. R.: Compliance, safety and effectiveness of fixed dose combinations of antihypertensive agents: a meta-analysis. *Hypertension*, 2010, 55, s. 399–407.
- 14 Suvila, K. – McCabe, E. L. – Lehtonen, A., et al.: Early onset hypertension is associated with hypertensive end-organ damage already by midlife. *Hypertension*, 2019, 74, s. 305–312.

Perindopril s indapamidem ve fixní kombinaci k léčbě arteriální hypertenze u obézního nemocného s prediabetem – kazuistika

prof. MUDr. Robert Holaj, CSc., MBA Centrum pro výzkum, diagnostiku a léčbu hypertenze, III. interní klinika, 1. LF UK a VFN, Praha

- 1 Cifkova, R. – Bruthans, J. – Strlichuk, L., et al.: Longitudinal trends in blood pressure, prevalence, awareness, treatment, and control of hypertension in the Czech population. Are there any sex differences? *Front Cardiovasc Med*, 2022, 9, 1033606.
- 2 Farsang, C.; investigátoři studie PICASSO: Blood pressure and metabolic efficacy of fixed-dose combination of perindopril and indapamide in everyday practice. *Blood Press*. 2013, 22, suppl. 1, s. 3–10.
- 3 Farsang, C. – Dezi, C. A. – Brzozowska-Villatte, R., et al.: Beneficial effects of a perindopril/indapamide single-pill combination in hypertensive patients with diabetes and/or obesity or metabolic syndrome: a post hoc pooled analysis of four observational studies. *Adv Ther*, 2021, 38, s. 1776–1790.
- 4 Nazarzadeh, M. – Bidel, Z. – Canoy, D., et al.: Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. *Lancet*, 2021, 398, s. 1803–1810.
- 5 Patel, A. – Group, A. C. – MacMahon, S., et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*, 2007, 370, s. 829–840.
- 6 Beckett, N. S. – Peters, R. – Fletcher, A. E., et al.: Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*, 2008, 358, s. 1887–1898.
- 7 Chalmers, J. – Mourad, J. J. – Brzozowska-Villatte, R., et al.: Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials. *J Hypertens*, 2023, 41, s. 508–515.

Deprese a kardiovaskulární choroby v kontextu zánětlivých procesů

MUDr. Eva Kitzlerová, Ph.D. Psychiatrická klinika 1. LF UK a VFN, Praha

- 1 Wittchen, H. U. – Jacobi, F. – Rehm, J., et al.: The size and burden of mental disorders and other disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol*, 2011, 21, s. 655–679.
- 2 GBD 2017 Disease and Injury Incidence and Prevalence Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*, 2018, 392, s. 1789–858.
- 3 Steffen, A. – Nübel, J. – Jacobi, F., et al.: Mental and somatic comorbidity of depression: a comprehensive cross-sectional analysis of 202 diagnosis groups using German nation wide ambulatory claims data. *BMC Psychiatry*, 2020, 20, s. 142–157.
- 4 Vacarino, V.: The association between depression and coronary heart disease incidence. *Drugs Today*, 2000, 36, s. 715–724.
- 5 Daskalopoulou, M. – George, J. – Walters, K., et al.: Depression as a risk factor for the initial presentation of twelve cardiac, cerebrovascular, and peripheral arterial diseases: Data linkage study of 1.9 million women and men. *PLoS One*, 2016, 11, e0153838.
- 6 Penninx, B. W. J. H. – Beekman, A. T. F. – Honig, A., et al.: Depression and cardiac mortality. *Arch Gen Psychiatry*, 2001, 58, s. 221–227.
- 7 Grunau, G. L. – Ratner, P. A. – Goldner, E. M., et al.: Is early- and late-onset depression after acute myocardial infarction associated with long-term survival in older adults? A population-based study. *Can J Cardiol*, 2006, 22, s. 473–478.
- 8 Mitchell, A. J. – Vaze, A. – Rao, S.: Clinical diagnosis of depression in primary care: a meta-analysis. *Lancet*, 2009, 374, s. 609–619.
- 9 Grabe, H. J. – Lange, M. – Wolff, B., et al.: Mental and physical distress is modulated by a polymorphism in the 5-HT transporter gene interacting with social stressors and chronic disease burden. *Molecular Psychiatry*, 2005, 10, s. 220–224.
- 10 De Hert, M. – Detraux, J. – Vancampfort, D.: The intriguing relationship between coronary heart disease and mental disorders. *Dialogues Clin Neurosci*, 2018, 20, s. 31–39.
- 11 Pelletier, R. – Bacon, S. L. – Arsenault, A., et al.: Relative associations between depression and anxiety on adverse cardiovascular events: does a history of coronary artery disease matter? A prospective observational study. *BMJ Open*, 2015, 5, e006582.
- 12 Furman, D. – Campisi, J. – Verdin, E., et al.: Chronic inflammation in the etiology of disease across the life span. *Nature Medicine*, 2019, 25, s. 1822–1832.
- 13 Beurel, E. – Touns, M. – Nemeroff, C. B.: The bidirectional relationship of depression and inflammation: double trouble. *Neuron*, 2020, 107, s. 234–256.
- 14 Straub, R. H.: The brain and immune system prompt energy shortage in chronic inflammation and ageing. *Nat Rev Rheumatol*, 2017, 13, s. 743–751.
- 15 Honig, A. – Maes, M.: Psychoimmunology as a common pathogenic pathway in myocardial infarction, depression and cardiac death. *Curr Opin Psychiatry*, 2000, 13, s. 661–664.
- 16 Shao, M. – Lin, X. – Jiang, D. – Tian, H., et al.: Depression and cardiovascular disease: Shared molecular mechanisms and clinical implications. *Psychiatry Research*, 2020, 285, s. 112802.
- 17 Mattina, G. F. – Van Lieshout, R. J. – Steiner, M.: Inflammation, depression and cardiovascular disease in women: the role of the immune system across critical reproductive events. *Thromb Haemostasis*, 2019, 13, 1753944719851950.
- 18 Severus, W. E. – Littman, A. B. – Stoll, A. L.: Omega-3 fatty acids, homocysteine, and the increased risk of cardiovascular mortality in major depressive disorder. *Harvard Rev Psychiatry*, 2001, 9, s. 280–293.
- 19 Fu, Y. – Wang, Y. – Gao, H., et al.: Associations among dietary omega-3 polyunsaturated fatty acids, the gut microbiota, and intestinal immunity. *Mediators Inflamm*, 2021, 2021, 8879227.
- 20 Mischoulon, D. – Dunlop, B. W. – Kinkead, B., et al.: Omega-3 fatty acids for major depressive disorder with high inflammation: a randomized dose-finding clinical trial. *J Clin Psychiatry*, 2022, 83, 21m14074.
- 21 Kitzlerová, E. – Anders, M.: Deprese a kardiovaskulární choroby – společný průnik na rovině psychosociální a behaviorální. *Česká a Slovenská Psychiatrie*, 2010, 106, s. 87–92.
- 22 Pearce, M. – Garcia, L. – Abbas, A., et al.: Association between physical activity and risk of depression: a systematic review and meta-analysis. *JAMA Psychiatry*, 2020, 77, s. 550–559.
- 23 Cojocariu, S. A. – Mastaleru, A. – Sascu, R. A., et al.: Relationships between psychoeducational rehabilitation and health outcomes – a systematic review focused on acute coronary syndrome. *J Pers Med*, 2021, 11, s. 440.
- 24 Frasure-Smith, N. – Lesperance, F.: Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery

disease. *Arch Gen Psychiatry*, 2008, 65, s. 62–71.

- 25 Antonogeorgos, G. – Panagiotakos, D. B. – Pitsavos, C., et al.: Understanding the role of depression and anxiety on cardiovascular disease risk, using structural equation modeling; the mediating effect of the Mediterranean diet and physical activity: the ATTICA study. *Ann Epidemiol*, 2012, 22, s. 630–637.
- 26 Wood, S. K.: Individual differences in the neurobiology of social stress: implications for depression-cardiovascular disease comorbidity. *Curr Neuropharmacol*, 2014, 12, s. 205–211.
- 27 Scherrer, J. F. – Chrusciel, T. – Zeringue, A., et al.: Anxiety disorders increase risk of incident myocardial infarction in depressed and non-depressed veterans administration patients. *Am Heart J*, 2010, 159, s. 772–779.
- 28 Schulz, S. M. – Massa, C. – Grziela, A., et al.: Implantable cardioverter defibrillator shocks are prospective predictors of anxiety. *Heart Lung*, 2013, 42, s. 105–111.
- 29 Larson, M. S. – McDonald, K. – Young, C., et al.: Quality of life before and after radiofrequency catheter ablation in patients with drug refractory atrioventricular nodal reentrant tachycardia. *Am J Cardiol*, 1999, 84, s. 471–473.
- 30 Kitzlerová, E. – Anders, M. – Kautzner, J., et al.: Evaluation of psychopathology in patients with paroxysmal supraventricular tachycardia. *Exp Clin Cardiol*, 2007, 12, s. 42–45.
- 31 Batelaan, N. M. – Seldenrijk, A. – Bot, M., et al.: Anxiety and new onset of cardiovascular disease: critical review and meta-analysis. *Br J Psychiatry*, 2016, 208, s. 223–231.
- 32 Pizzi, C. – Rutjes, A. W. – Costa, G. M., et al.: Meta-analysis of SSRIs in patients with depression and coronary heart disease. *Am J Cardiol*, 2011, 107, s. 972–979.
- 33 Glasman, A. H. – O'Connor, C. H. M. – Califf, R. M., P., et al.: Sertraline treatment of major depression in patients with acute MI or unstable angina. *JAMA*, 2002, 288, s. 701–709.
- 34 Taylor, C. B. – Youngblood, M. E. – Catellier, D., et al.: for the ENRICH Investigators: Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. *Arch Gen Psychiatry*, 2005, 62, s. 792–798.
- 35 Van den Brink, van Melle, J. P. – Honig, A., et al.: Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the myocardial infarction and depression – intervention Trial (MIND-IT). *Am Heart J*, 2002, 144, s. 219–225.
- 36 Sweda, R. – Siontis, G. C. M. – Nikolakopoulou, A., et al.: Antidepressant treatment in patients following acute coronary syndromes: a systematic review and Bayesian meta-analysis. *ESC Heart Failure*, 2020, 7, s. 3610–3620.
- 37 Prasitlumkum, N. – Cheungpasitporn, W. – Tokavanich, N., et al.: Antidepressants and risk of sudden cardiac death: a network meta-analysis and systematic review. *Med Sci*, 2021, 9, s. 26.
- 38 Behlke, L. M. – Lenze, E. J. – Carney, R. M.: The cardiovascular effects of newer antidepressants in older adults and those with at high risk for cardiovascular diseases. *CNS Drugs*, 2020, 34, s. 1133–1147.
- 39 Aronow, W. S. – Shamiyan, T. A.: Effects of antidepressants on QT interval in people with mental disorders. *Arch Med Sci*, 2020, 16, s. 727–741.
- 40 Kitzlerová, E.: Deprese u pacientů s kardiovaskulárním onemocněním – lze léčit bezpečně? *Med Praxi*, 2021, 18, s. 316–321.
- 41 Diez-Quevedo, C. – Lupón, J. – de Antonio, M., et al.: Benzodiazepine use and long-term mortality in real-life chronic heart failure outpatients: a cohort analysis. *Psychother Psychosom*, 2018, 87, s. 372–374.
- 42 Piña, I. L. – Di Palo, K. E. – Ventura, H. O.: Psychopharmacology and cardiovascular disease. *J Am Coll Cardiol*, 2018, 71, s. 2346–2359.
- 43 De Hert, M. – Detraux, J. – Vancampfort, D.: The intriguing relationship between coronary heart disease and mental disorders. *Dialogues Clin Neurosci*, 2018, 20, s. 31–40.
- 44 Masopust, J. – Kopeček, M. – Blaha, V.: Sledování tělesného zdraví u pacientů se závažnými neorganickými duševními poruchami (psychózy, bipolární porucha, depresevní porucha). Dostupné z: <http://postupy-pecce.psychieatrie.cz/obecna-psychieatrie/sledovani-telesneho-zdravi>, vyhledáno 5. 10. 2023.

Oční projevy interních onemocnění

doc. MUDr. Ján Lešták, CSc., MSc, MBA, LLA, DBA, FEBO, FAOG Fakulta biomedicínského inženýrství ČVUT v Praze

- 1 Keith, N. – Wagener, H. P. – Banker, N.: Some different pes of essential hypertension. The ircourse and prognosis. *AMJ Med Sci*, 1939, 197, s. 332.
- 2 Boguszaková, J.: In: Kraus, H., et al.: *Kompendium očního lékařství*. Grada Publishing, Praha, 1997.
- 3 Karel, I.: In: Kraus, H., et al.: *Kompendium očního lékařství*. Grada Publishing, Praha, 1997.
- 4 Lešták, J. – Vladyková, J. – Cigánek, L.: Anterioris chemi neuropathy of the optic nerve as visualized by perimetry. *Cesk Oftalmol*, 1988, 44, s. 16–22.
- 5 Otradovec, J.: *Klinická neurooftalmologie*, Grada Publishing, Praha, 2003.
- 6 Lešták, J. – Vladyková, J. – Houšťava, L.: Compression less on sof the chiasmal area from the viewpoint of the ophthalmologist. *Cesk Slov Oftalmol*, 1995, 51, s. 165–170.
- 7 Kyncl, M. – Kasl, Z. – Rusňák, Š. – Sobotová, M. – Krčma, M. – Tintěra, J. – Fůs, M. – Lešták, J.: Pituitary apoplexy with out chiasm compression: A case report. *Mol Clin Oncol*, 2021, 15, s. 176.
- 8 Karhanová, M. – Kalitová, J.: Endokrinní orbitopatie z pohledu oftalmologa. *Med Praxi*, 2013, 10, s. 68–71.
- 9 Kalvodová, B. – Dubska, Z. – Kousal, B., et al.: In: Heissigerová, J., et al.: *Oftalmologie*. Maxdorf, Praha, 2018.
- 10 Pasadhika, S. – Rosenbaum, J. T.: Ocular Sarcoidosis. *Clin Chest Med*, 2015, 36, s. 669–683.
- 11 Kyncl, M. – Fús, M. – Lestak, J.: Ethambutol-induced optic neuropathy. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*, DOI: 10.5507/bp.2022.022.
- 12 Němčanská, S. – Stepanov, A. – Němčanský, J.: Ophthalmic manifestations of acute leukaemias. *Ces Slov Oftalmol*, 2018, 74, s. 98–101.
- 13 Kanski, J. J.: *Clinical ophthalmology*. Edinburgh, Butterworth-Heinemann, 2003, s. 485–486.
- 14 Říhová, E.: *Uveitidy*. Grada, Praha, 2009.
- 15 Kanvinde, S. – Bhargava, P. – Patwardhan, S.: Cytomegalovirus infection as a cause of cytopenia after chemotherapy for hematological malignancies. *Indian Pediatrics*, 2013, 50, s. 197–201.
- 16 Lestak, J. – Mlčák, P. – Kuba, A., et al.: Bilateral optic neuropathy as a complication of allogeneic hematopoietic stem cell transplantation. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*, 2023, 167, s. 199–207.
- 17 Lešták, J. – Voldřich, Z. – Houšťava, L., et al.: Tumors and pseudotumors of the orbit and their surgical removal. *J Clin Exp Ophthalmol*, 2014, 5, s. 321.
- 18 Chylova, H. – Dubska, Z. – Kyncl, M. – Fús, M. – Lešták, J.: Optic neuropathy associated with acute pancreatitis: A case report. *Exp Ther Med*, 2022, 25, s. 58.

Kožní změny u interních pacientů – vitiligo

MUDr. Barbora Divišová, Ph.D. Dermafit Centrum, s. r. o., Plzeň

- 1 Hercogová, J., et al.: *Klinická dermatovenerologie*. Mladá fronta, Praha, 2019, kap. Vitiligo, s. 442–451.
- 2 Lee, J., et al.: Comorbidities in patients with viligo: a systematic review and meta-analysis. *J Invest Dermatol*, 2023, 143, s. 777–789.
- 3 Chivu, A. M., et al.: Vitiligo – thyroid disease association: when, in whom, and why should it be suspected? *J Pers Med*, 2022, 12, s. 2048.
- 4 Orphelin, J. M., et al.: Cutaneous manifestations induced by checkpoint inhibitors in 120 melanoma patients – The European MelSkin-TOX Study. *J Eur Acad Dermatol Venereol*, 2023, 37, s. 1606–1615.
- 5 Iwamoto, Y., et al.: Immune checkpoint inhibitor – induced hypothyroidism predicts treatment response in Japanese subjects. *Front Endocrinol*, 2023, 14, 1221723.
- 6 Chang, H. C., et al.: The association between vitiligo and diabetes mellitus? A systematic review and meta-analysis. *J Am Acad Dermatol*, 2019, 81, s. 1442–1445.
- 7 Böhm, M., et al.: S1 Guideline: Diagnosis and therapy of vitiligo. *J Dtsch Dermatol Ges*, 2022, 20, s. 365–378.
- 8 Fenf, Y. – Lu, Y.: Advances in vitiligo: Update on therapeutic targets. *Front Immunol*, 2022, 13, 986918.

Dapagliflozin v ordinaci internisty

prof. MUDr. David Karásek, Ph.D. III. interní klinika – nefrologická, revmatologická a endokrinologická, LF UP a FN Olomouc

- 1 Dhillon, S.: Dapagliflozin: a review in type 2 diabetes. *Drugs*, 2019, 79, s. 1135–1146.
- 2 Feng, M. – Lv, H. – Xu, X., et al.: Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. *Medicine*, 2019, 98, s. e16575.
- 3 Inzucchi, S. E. – Zinman, B. – Wanner, C., et al.: SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. *Diab Vasc Dis Res*, 2015, 12, s. 90–100.
- 4 Rajasekeran, H. – Lytvyn, Y. – Cherney, D. Z.: Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. *Kidney Int*, 2016, 89, s. 524–526.
- 5 ElSayed, N. A. – Aleppo, G. – Aroda, V. R., et al.: on behalf of the American Diabetes Association: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. *Diabetes Care*, 2023, 46, suppl. 1, s. S140–S157.
- 6 Chen, H. B. – Meng, R. S. – Yang, Y. L., et al.: The risk of all-cause death with dapagliflozin versus placebo: a systematic review and meta-analysis of phase III randomized controlled trials. *Expert Opin Drug Saf*, 2023, 22, s. 133–140.
- 7 Dostupné z: https://prehledy.sukl.cz/prehled_leciv.html#/leciva/0193661, vyhledáno 27. 9. 2023.
- 8 Wiviott, S. D. – Raz, I. – Bonaca, M. P., et al.: DECLARE-TIMI 58 Investigators: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2019, 380, s. 347–357.
- 9 McMurray, J. J. V. – Solomon, S. D. – Inzucchi, S. E., et al.: DAPA-HF Trial Committees and Investigators: Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*, 2019, 381, s. 1995–2008.
- 10 Solomon, S. D. – McMurray, J. J. V. – Claggett, B., et al.: DELIVER Trial Committees and Investigators: Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med*, 2022, 387, s. 1089–1098.
- 11 Packer, M. – Anker, S. D. – Butler, J., et al.: EMPEROR-Reduced Trial Investigators: Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med*, 2020, 383, s. 1413–1424.
- 12 Anker, S. D. – Butler, J. – Filippatos, G., et al.: EMPEROR-Preserved Trial Investigators: Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med*, 2021, 385, s. 1451–1461.
- 13 Sattar, N. – McLaren, J. – Kristensen, S. L., et al.: SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? *Diabetologia*, 2016, 59, s. 1333–1339.
- 14 Verma, S. – McMurray, J. J. V. – Cherney, D. Z. I.: The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. *JAMA Cardiol*, 2017, 2, s. 939–940.
- 15 McDonagh, T. A. – Metra, M. – Adamo, M., et al.: 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2023, doi: 10.1093/eurheartj/ehad195.
- 16 Scheen, A. J.: Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. *Circ Res*, 2018, 122, s. 1439–1459.
- 17 Shin, S. J. – Chung, S. – Kim, S. J., et al.: Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. *PLoS One*, 2016, 11, e0165703.
- 18 Tarnaglo, J.: Sodium-glucose cotransporter 2 inhibitors in heart failure: potential mechanisms of action, adverse effects and future developments. *Eur Cardiol*, 2019, 14, s. 23–32.
- 19 Lopaschuk, G. D. – Verma, S.: Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. *JACC Basic Transl Sci*, 2020, 5, s. 632–644.
- 20 Nevala, R. – Alfano, M. – Pafundi, P. C., et al.: Cardiorenal impact of SGLT-2 inhibitors: a conceptual revolution in the management of type 2 diabetes, heart failure and chronic kidney disease. *Rev Cardiovasc Med*, 2022, 23, s. 106.
- 21 Heerspink, H. J. L. – Stefánsson, B. V. – Correa-Rotter, R., et al.: DAPA-CKD Trial Committees and Investigators: Dapagliflozin in patients with

chronic kidney disease. *N Engl J Med*, 2020, 383, s. 1436–1446.
22 Perkovic, V. – Jardine, M. J. – Neal, B., et al.: CREDESCENCE Trial Investigators: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*, 2019, 380, s. 2295–2306.

23 Herrington, W. G. – Staplin, N. – Wanner, C., et al.: The EMPA-KIDNEY Collaborative Group: Empagliflozin in patients with chronic kidney disease. *N Engl J Med*, 2023, 388, s. 117–127.
24 Rossing, P. – Inzucchi, S. E. – Vart, P., et al.: DAPA-CKD and DAPA-HF

Trial Committees and Investigators: Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. *Lancet Diabetes Endocrinol*, 2022, 10, s. 24–34.

Inkretiny (GIP a GLP-1) – aktuální pohled na patofyziologii a klinické perspektivy

prof. MUDr. Jan Škrha, DrSc., MBA III. interní klinika endokrinologie a metabolismu 1. LF UK a VFN, Praha

- Creutzfeldt, W.: The incretin concept today. *Diabetologia*, 1979, 16, s. 75–85.
- Holst, J. J. – Ørskov, C. – Vagn-Nielsen, O., et al.: Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. *FEBS Lett*, 1987, 211, s. 169–174.
- Nauck, M. A. – Heimesaat, M. M. – Ørskov, C., et al.: Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. *J Clin Invest*, 1993, 91, s. 301–307.
- Nauck, M. A. – Meier, J. J.: Incretin hormones: Their role in health and disease. *Diabetes Obes Metab*, 2018, 20, suppl. 1, s. 5–21.
- Nauck, M. A. – Quast, D. R. – Wefers, J., et al.: The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. *Diabetes Obes Metab*, 2021, 23, suppl. 3, s. 5–29.
- Nauck, M. A. – Heimesaat, M. M. – Behle, K., et al.: Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. *J Clin Endocrinol Metab*, 2002, 87, s. 1239–1246.
- Gasbjerg, L. S. – Bergmann, N. C. – Stensen, S., et al.: Evaluation of the incretin effect in human using GIP and GLP-1 receptor antagonists. *Peptides*, 2020, 125, s. 170–183.
- Hvidberg, A. – Nielsen, M. T. – Hilsted, J., et al.: Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. *Metabolism*, 1994, 43, s. 104–108.
- Meier, J. J. – Gallwitz, B. – Siepmann, N., et al.: Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycemia. *Diabetologia*, 2003, 46, s. 798–801.
- Bergmann, N. C. – Lund, A. – Gasbjerg, L. S., et al.: Effect of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. *Diabetologia*, 2019, 62, s. 665–675.
- Samms, R. J. – Coghlan, M. P. – Sloop, K. W.: How may GIP enhance the therapeutic efficacy of GLP-1? *Trends Endocrinol Metab*, 2020, 31, s. 410–421.
- Asmar, M. – Arrgrim, N. – Simonsen, L., et al.: The blunted effect of glucose-dependent insulinotropic polypeptide in subcutaneous abdominal adipose tissue in obese subjects is partly reversed by weight loss. *Nutr Diabetes*, 2016, 6, s. e208.
- Mantelmacher, F. D. – Zvibel, I. – Cohen, K., et al.: GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9. *Nat Metab*, 2019, 1, s. 58–69.
- Schirra, J. – Göke, B.: The physiological role of GLP-1 in human: incretin, ileal brake or more? *Regul Pept*, 2005, 128, s. 109–115.
- Mabileau, G. – Mieczkowska, A. – Chappard, D.: Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. *J Diabetes*, 2014, 6, s. 260–266.
- Højberg, P. V. – Vilsbøll, T. – Rabøl, R., et al.: Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. *Diabetologia*, 2009, 52, s. 199–207.
- Mentis, N. – Vardarli, I. – Köthe, L. D., et al.: GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. *Diabetes*, 2011, 60, s. 1270–1276.
- Samms, R. J. – Coghlan, M. P. – Sloop, K. W.: How may GIP enhance the therapeutic efficacy of GLP-1? *Trends Endocrinol Metab*, 2020, 31, s. 410–421.
- Coskun, T. – Sloop, K. W. – Loghin, C., et al.: LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. *Molec Metab*, 2018, 18, s. 3–14.
- Frias, J. P. – Nauck, M. A. – Van, J., et al.: Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo controlled and active comparator-controlled phase 2 trial. *Lancet*, 2018, 392, s. 2180–2193.
- Thomas, M. K. – Nikoienjad, A. – Bray, R., et al.: Tirzepatide, a dual GIP and GLP-1 receptor agonist, improves markers of beta cell function and insulin sensitivity in type 2 diabetes patients. *Diabetologia*, 2019, 62, s. S354–S354.
- Min, T. – Bain, S. C.: The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials. *Diabetes Ther*, 2021, 12, s. 143–157.
- Frias, J. P. – Davis, M. J. – Rosenstock, J., et al.: Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. *New Engl J Med*, 2021, 385, s. 503–515.
- DelPrato, S. – Kahn, S. E. – Pavo, I., et al.: Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet*, 2021, 398, s. 1811–1824.
- Ludvik, B. – Giorgino, F. – Jódar, E., et al.: Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. *Lancet*, 2021, 398, s. 583–598.
- Wang, L.: Designing a dual GLP-1R/GIPR agonist from tirzepatide: comparing residues between tirzepatide, GLP-1, and GIP. *Drug Des Devel Ther*, 2022, 16, s. 1547–1559.

Infekční komplikace u syndromu diabetické nohy

MUDr. Dominika Sojáková Centrum diabetologie IKEM a 1. LF UK, Praha MUDr. Radka Jarošíková | MUDr. Vladimíra Fejfarová, Ph.D.

Centrum diabetologie IKEM a 2. LF UK, Praha MUDr. Michal Dubský, Ph.D. FRSPH Centrum diabetologie IKEM a 1. LF UK, Praha

- Jirkovská, A. – Dubský, M. – Fejfarová, V.: *Syndrom diabetické nohy – prevence, diagnostika a terapie. Adaptovaný doporučený postup na základě mezinárodních guidelines*. Geum, Semily, 2022, s. 126–127.
- Lavery, L. A. – Oz, O. K. – Bhavan, K., et al.: Diabetic foot syndrome in the twenty first century. *Clin Podiatr Med Surg*, 2019, 36, s. 355–355.
- Hurlow, J. J. – Humphreys, G. J. – Bowling, F. L., et al.: Diabetic foot infection: A critical complication. *Int Wound J*, 2018, 15, s. 814–821.
- Ndosi, M. – Wright-Hughes, A. – Brown, S., et al.: Prognosis of the infected diabetic foot ulcer: a 12-month prospective observational study. *Diabet Med*, 2018, 35, s. 78–88.
- Bem, R.: Infekční komplikace syndromu diabetické nohy – diagnostika a léčba. *Vnitř Lek*, 2023, 69, s. 25–30.
- Pitocco, D. – Spanu, T. – Di Leo, M., et al.: Diabetic foot infections: a comprehensive overview. *Eur Rev Med Pharmacol Sci*, 2019, 23, suppl., s. 26–37.
- Bem, R. – Dubský, M. – Fejfarová, V., et al.: Diabetická noha. *Vnitř Lek*, 2020, 66, s. 92–97.
- Lázaro Martínez, J. L. – García Álvarez, Y. – Tardáguila-García, A., et al.: Optimal management of diabetic foot osteomyelitis: challenges and solutions. *Diabetes Metab Syndr*, 2019, 12, s. 947–959.
- Senneville, E. M. – Lipsky, B. A. – van Asten, S. A. V., et al.: Diagnosing diabetic foot osteomyelitis. *Diabetes Metab Res Rev*, 2020, 36, suppl. 1, s. e3250.
- Senneville, E. – Albalawi, Z. – van Asten, S. A., et al.: IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). *Diabetes Metab Res Rev*, 2023, s. e3687.
- Morales Lozano, R. – González Fernández, M. L. – Martínez Hernández, D., et al.: Validating the probe-to-bone test and other tests for diagnosing chronic osteomyelitis in the diabetic foot. *Diabetes Care*, 2010, 33, s. 2140–2145.
- Lavery, L. A. – Ahn, J. – Ryan, E. C., et al.: What are the optimal cut off values for ESR and CRP to diagnose osteomyelitis in patients with diabetes-related foot infections? *Clin Orthop Relat Res*, 2019, 477, s. 1594–1602.
- Xu, J. – Cheng, F. – Li, Y., et al.: Erythrocyte sedimentation rate combined with the probe-to-bone test for fast and early diagnosis of diabetic foot osteomyelitis. *Int J Low Extrem Wounds*, 2021, 20, s. 227–231.
- Tone, A. – Nguyen, S. – Devemy, F., et al.: Six-week versus twelve-week antibiotic therapy for non surgically treated diabetic foot osteomyelitis: a multicenter open-label controlled randomized study. *Diabetes Care*, 2015, 38, s. 302–307.
- Iranparvar, M. – Arzanlou, O. – Afrouzeh, E.: Comparison of the efficacy of six-week versus twelve-week antibiotic therapy for the treatment of nonsurgical diabetic foot osteomyelitis. *Int Med*, 2019, 1, s. 274–279.
- Gardner, S. E. – Hillis, S. L. – Frantz, R. A.: Clinical signs of infection in diabetic foot ulcers with high microbial load. *Biol Res Nurs*, 2009, 11, s. 119–128.
- Citron, D. M. – Goldstein, E. J. – Merriam, C. V., et al.: Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. *J Clin Microbiol*, 2007, 45, s. 2819–2828.
- Fejfarová, V. – Jirkovská, A. – Petkov, V., et al.: Comparison of microbial findings and resistance to antibiotics between transplant patients, patients on hemodialysis, and other patients with the diabetic foot. *J Diabetes Complications*, 2004, 18, s. 108–112.
- Macdonald, K. E. – Boeckh, S. – Stacey, H. J., et al.: The microbiology of diabetic foot infections: a meta-analysis. *BMC Infect Dis*, 2021, 21, s. 770.
- Fejfarová, V. – Skořepová, M. – Jirkovská, A., et al.: Diagnostika a léčba mykotických infekcí. *HPB Bulletin*, 2006, 14, s. 147–150.
- Pham, T. T. – Gariani, K. – Richard, J. C., et al.: Moderate to severe soft tissue diabetic foot infections: a randomized, controlled, pilot trial of post-debridement antibiotic treatment for 10 versus 20 days. *Ann Surg*, 2022, 276, s. 233–238.
- Saeed, K. – Esposito, S. – Akram, A., et al.: International Society of Antimicrobial Chemotherapy. Hot topics in diabetic foot infection. *Int J Antimicrob Agents*, 2020, 55, s. 105942.
- Weintrob, A. C. – Sexton, D. J.: Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Dostupné z: <https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-management-of-diabetic-infections-of-the-lower-extremities>, vyhledáno 29. 8. 2023.
- Lipsky, B. A., et al.: Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. *Clin Infect Dis*, 2012, 54, s. e132.

Léčba bolesti v interní ambulanci

MUDr. Jan Procházka, Ph.D. Centrum léčby chronické bolesti při KAPIM, KZ, a. s., Masarykova nemocnice Ústí nad Labem

- Hakl, M., et al.: *Bolesti zad a kloubů*. Mladá fronta, Praha, 2017.
- Holý, J. – Pešková, M.: Lékové interakce a současná klinická praxe. *Kardiol Rev Int Med*, 2015, 17, s. 70–75.
- Kolektiv: Metodické pokyny pro farmakoterapii chronické bolesti. *Bolest*, 2022, 25, suppl. 1, s. 1–40. Dostupné z: https://www.tigis.cz/images/stories/Bolest/2022/Bolest_suppl_1_2022/pokyny_Bolest_suppl_1_2022.pdf, vyhledáno 21. 7. 2023.
- Kosek, E. – Cohen, M. – Baron, R., et al.: Do we need a third mechanistic descriptor for chronic pain states? *Pain*, 2016, 157, s. 1382–1386.
- Procházka, J.: Jaké jsou současné možnosti ambulance bolesti a kdy tam posílat pacienty? *Med Praxi*, 2016, 13, s. 106–111.
- Procházka, J.: Serotoninový syndrom a léčba bolesti. *Neural Praxi*, 2023, v tisku.
- Rokyta, R., et al.: *Léčba bolesti v primární péči*. Grada, Praha, 2018.
- Rokyta, R. – Kozák, J. – Kršík, M.: *Bolest*. Tigis, Praha, 2012.

Refluxní choroba jícnu – současný pohled

MUDr. Tomáš Skutil | MUDr. Štefan Konečný | MUDr. Jitka Vaculová Interní gastroenterologická klinika FN a LF MU, Brno

- Vakil, N. – van Zanten, S. V. – Kahrilas, P., et al.: Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol*, 2006, 101, s. 1900–1943.
- Castell, D. O. – Murray, J. A. – Tutuian, R., et al.: The pathophysiology of gastro-oesophageal reflux disease – oesophageal manifestations. *Aliment Pharmacol Ther*, 2004, 20, s. 14–25.
- Hershovici, T. – Fass, R.: Nonerosive reflux disease (NERD) – an update. *J Neurogastroenterol Motil*, 2010, 16, s. 8–21.
- Katz, P. O. – Dunbar, K. B. – Schnoll-Sussman, F. H., et al.: ACG Clinical Guideline for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol*, 2022, 117, s. 27–56.
- El-Serafi, H. B. – Sweet, S. – Winchester, C. C., et al.: Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. *Gut*, 2014, 63, s. 871–880.
- Lukáš, K. – Bureš, J. – Drahoňovský, V., et al.: Refluxní choroba jícnu. Standardy České gastroenterologické společnosti – aktualizace 2009. *Vnitřní Léč*, 2009, 55, s. 967–975.
- Jewett, T. C. Jr. – Siegel, M.: Hiatal hernia and gastroesophageal reflux. *J Pediatr Gastroenterol Nutr*, 1984, 3, s. 340–345.
- Hampel, H. – Abraham, N. S. – El-Serafi, H. B.: Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. *Ann Intern Med*, 2005, 143, s. 199–211.
- Yuan, S. – Larsson, S. C.: Adiposity, diabetes, lifestyle factors and risk of gastroesophageal reflux disease: a Mendelian randomization study. *Eur J Epidemiol*, 2022, 37, s. 747–754.
- Scida, S. – Russo, M. – Miraglia, C., et al.: Relationship between Helicobacter pylori infection and GERD. *Acta Biomed*, 2018, 89, s. 40–43.
- Yeom, J. S. – Park, H. J. – Cho, J. S., et al.: Reflux esophagitis and its relationship to hiatal hernia. *J Korean Med Sci*, 1999, 14, s. 253–256.
- Trimble, K. C. – Pryde, A. – Heading, R. C.: Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. *Gut*, 1995, 37, s. 7–12.
- Ang, D. – How, C. H. – Ang, T. L.: Persistent gastro-oesophageal reflux symptoms despite proton pump inhibitor therapy. *Singapore Med J*, 2016, 57, s. 546–551.
- Ang, D. – How, C. H. – Ang, T. L.: Persistent gastro-oesophageal reflux symptoms despite proton pump inhibitor therapy. *Singapore Med J*, 2016, 57, s. 546–551.
- Clarett, D. M. – Hachem, C.: Gastroesophageal reflux disease (GERD). *Mo Med*, 2018, 115 s. 214–218.
- Sandhu, D. S. – Fass, R.: Current trends in the management of gastroesophageal reflux disease. *Gut Liver*, 2018, 12, s. 7–16.
- Cesario, S. – Scida, S. – Miraglia, C., et al.: Diagnosis of GERD in typical and atypical manifestations. *Acta Biomed*, 2018, 89, s. 33–39.
- Brandt, P. – Lukáš, K. – Turzík, J., et al.: Extraezofageální refluxní choroba – mezioborový konsenzus. *Čas Lék Čes*, 2011, 150, s. 513–518.
- Gyawali, C. P. – Kahrilas, P. J. – Savarino, E., et al.: Modern diagnosis of GERD: the Lyon Consensus. *Gut*, 2018, 67, s. 1351–1362.
- Bredenoord, A. J. – Pandolfino, J. E. – Smout, A. J. P. M.: Gastro-oesophageal reflux disease. *Lancet*, 2013, 381, s. 1933–1942.
- Roman, S. – Gyawali, C. P. – Savarino, E., et al.: Ambulatory reflux monitoring for diagnosis of gastro-oesophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. *Neurogastroenterol Motil*, 2017, 29, s. 1–15.
- Armstrong, D.: Endoscopic evaluation of gastro-oesophageal reflux disease. *Yale J Biol Med*, 1999, 72, s. 93–100.
- Kroupa, R. – Konečný, Š. – Dolina, J.: Současné trendy v diagnostice a léčbě refluxní nemoci jícnu. *Vnitřní Léč*, 2018, 64, s. 588–594.
- Zhang, J. X. – Ji, M. Y. – Song, J., et al.: Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. *World J Gastroenterol*, 2013, 19, s. 8408–8419.
- Khan, M. – Santana, J. – Donnellan, C., et al.: Medical treatments in the short term management of reflux oesophagitis. *Cochrane Database Syst Rev*, 2007, CD003244.
- Yibirin, M. – De Oliveira, D. – Valera, R., et al.: Adverse effects associated with proton pump inhibitor use. *Cureus*, 2021, 13, s. e12759.

Idiopatické střevní záněty – farmakologická léčba, současné možnosti, výhledy

MUDr. Hana Nováková, Ph.D. Interní gastroenterologická klinika FN Brno a LF Masarykovy univerzity, Brno

- Lémann, M. – Mary, J.-Y. – Duclos, B., et al.: Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: A randomized placebo-controlled trial. *Gastroenterology*, 2006, 130, s. 1054–1061.
- Panaccione, R. – Ghosh, S. – Middleton, S., et al.: Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. *J Crohns Colitis*, 2011, 5, s. 13.
- Mackery, A. C. – Green, L. – Liang, L. C., et al.: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. *J Pediatr Gastroenterol Nutr*, 2007, 44, s. 265–267.
- Gisbert, J. P. – Marin, A. C. – McNicholl, A. G., et al.: Systemic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. *Aliment Pharmacol Ther*, 2015, 41, s. 613–623.
- Zbořil, V.: *Idiopatické střevní záněty*. Mladá Fronta, Aeskulap Praha, 2018, s. 429–436.
- Chang, J. T.: Pathophysiology of inflammatory bowel disease. *N Engl J Med*, 2020, 386, s. 2652–2664.
- Kohn, A.: Effectiveness and long-term outcome of infliximab treatment for severe ulcerative colitis: an Italian multicentre open-label study. *Gut*, 2006, suppl. VI, s. A42.
- Ferrante, M. – Vermiere, S. – Fidler, H., et al.: Long-term outcome after infliximab for refractory ulcerative colitis. *J Crohns Colitis*, 2008, 3, s. 219–225.
- Ryan, B. M. – Russel, G. M. V. M. – Schurgers, L., et al.: Effect of anti-tumor necrosis factor- α therapy on bone turnover in patients with active Crohn's disease: a prospective study. *Aliment Pharmacol Ther*, 2004, 20, s. 851–857.
- Krejsek, J.: Modulation signálních drah IL-12/IL-23 ustekinumabem tlumí poškozující zánět u pacientů s Crohnovou nemocí. *Gastroenterol Hepatol*, 2018, 74, s. 334–339.
- Rutgeerts, P. – Gasink, C. – Blank, M., et al.: A multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL12/23p40 monoclonal antibody, in moderate-to-severe Crohn's disease refractory to anti-TNF α : UNIFI-1. *IBD*, 2016, 22, suppl. 1, S1.
- Feagan, B. – Gasink, C. – Lang, Y., et al.: A multicenter, double-blind, placebo-controlled pH3 study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately-to-severely active Crohn's disease who are not naive or not refractory to anti-TNF α : UNIFI-2. *UEG Journal*, 2015, 3, s. 563–564.
- Khorrani, A. – Gindir, D. – Marin Jimenez, I., et al.: Ustekinumab for treatment of refractory Crohn's disease: The Spanish experience in a large multicenter open-label cohort. *IBD*, 2016, 22, s. 1662–1669.
- Sandborn, W. J. – Colombel, J. F. – Frankel, M., et al.: Anti-CD3 visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. *Gut*, 2010, 29, s. 1485–1492.
- Creed, T. J. – Probert, C. S. – Norman, M. N., et al.: Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. *Aliment Pharmacol Ther*, 2006, 23, s. 1435–1442.
- Van Assche, G. – Sandborn, W. J. – Feagan, B. G., et al.: Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomized, double blind, placebo controlled, dose ranging trial. *Gut*, 2006, 55, s. 1568–1574.
- Tilig, H. – Vogelsang, H. – Ludwiczek, O., et al.: A randomised placebo controlled trial of pegylated interferon alpha in ulcerative colitis. *Gut*, 2003, 52, s. 1728–1733.
- Sandborn, W. J. – Colombel, J. F. – Sands, B. E., et al.: Abatacept for Crohn's disease and ulcerative colitis. *Gastroenterol*, 2012, 143, s. 62–69.
- Abdo Khaled, A. I. – Tye, G. J.: Interleukin 23 and autoimmune disease: current and possible future therapies. *Inflam Res*, 2020, 69, s. 463–480.
- Feagan, B. G. – Sandborn, W. J. D. – Haens, G., et al.: Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double blind, placebo-controlled phase 2 study. *Lancet*, 2017, 389, s. 1699–1709.
- Danese, S. – Gomollon, F.: Governing board and operational board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). *J Crohns Colitis*, 2013, 7, s. 586–589.
- Bortlík, M. – Ďuricová, D. – Kohout, P., et al.: Doporučení pro podávání biologické léčby pacientům s idiopatickými střevními záněty: třetí, aktualizované vydání. *Gastroenterol Hepatol*, 2016, 70, s. 11–27.
- Bortlík, M. – Ďuricová, D. – Douda, T., et al.: Doporučení pro podávání biologické léčby pacientům s idiopatickými střevními záněty. 4. aktualizované vydání. *Gastroenterol Hepatol*, 2019, 73, s. 11–24.

Praktické zkušenosti s léčbou inhibitory komplementu u paroxysmální noční hemoglobinurie

MUDr. Libor Červinek, Ph.D. Interní hematologická a onkologická klinika Fakultní nemocnice Brno

prof. MUDr. Pavel Žák, Ph.D. IV. interní hematologická klinika LF UK a FN Hradec Králové

MUDr. Jacqueline Soukupová Maaloufová Ústavu hematologie a krevní transfuze Praha

MUDr. Lenka Nosáková, PhD. | MUDr. Kristína Cmarková Klinika viscerální, všeobecné a transplantace chirurgie, Univerzitní nemocnice Martin, Jesseniova lékařská fakulta Martin, Univerzita Komenského Bratislava | MUDr. Jakub Hoferica | MUDr. Matuš

Ščur | MUDr. Juraj Chudej, PhD. | doc. MUDr. Peter Bánovčín, PhD. Interní klinika gastroenterologická, Univerzitní nemocnice

Martin, Jesseniova lékařská fakulta Martin, Univerzita Komenského Bratislava

- Lee, J. W. – Sicre de Fontbrune, F. – Wong Lee Lee, et al.: Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. *Blood*, 2019, 133, s. 530–539.
- Kulasekararaj, A. G. – Hill, A. – Rottinghaus, S. T., et al.: Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. *Blood*, 2019, 133, s. 540–549.
- Brodsky, R. A. – de Latour, R. P. – Rottinghaus, S. T., et al.: A prospective analysis of breakthrough hemolysis in 2 phase 3 randomized studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. *Blood*, 2018, 132, suppl. 1, s. 2330.
- Bhak, R. H., et al.: Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. *Curr Med Res Opin*, 2021, 37, s. 1913–1923.
- Hillmen, P., et al.: Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. *N Engl J Med*, 2021, 384, s. 1028–1037.
- De Latour, R. P., et al.: Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active comparator, controlled trial. *Lancet Haematol*, 2022, 9, s. e648–e659.
- Frickhofen, N. – Heimpel, H. – Kaltwasser, J. P., et al.: German Aplastic Anemia Study Group: Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. *Blood*, 2003, 101, s. 1236–1242.
- Delvasto-Nuñez, L. – Jongerius, I. – Zeeleeder, S.: It takes two to thrombose: Hemolysis and complement. *Blood Rev*, 2021, 50, 100834.

- 9 **Griffin, M. – Munir, T.**: Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide. *Ther Adv Hematol*, 2017, 8, s. 119–126.
- 10 **Risitano, A. M. – Marotta, S. – Ricci, P., et al.**: Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. *Front Immunol*, 2019, 10, s. 1157.
- 11 **Risitano, A. M., et al.**: How we(II) treat paroxysmal nocturnal haemoglobinuria: diving into the future. *Br J Haematol*, 2022, 196, s. 288–303.

Mnohočetný myelom – jak ho nepřehlédnout – kazuistika a rychlý přehled

MUDr. Jan Vachek, MHA Klinika nefrologie, 1. LF UK a VFN, Praha

- 1 **Kyle, R. – Greipp, P.**: Smoldering multiple myeloma. *N Engl J Med*, 1980, 302, s. 1347–1349.
- 2 **Dispenzieri, A. – Kyle, R. A. – Katzmann, J. A., et al.**: Immunoglobulin free lightchain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. *Blood*, 2008, 111, s. 785–789.
- 3 **Pérez-Persona, E. – Mateo, G. – García-Sanz, R., et al.**: Risk of progression in smoldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. *Br J Haematol*, 2010, 148, s. 110–114.
- 4 **Neben, K. – Jauch, A. – Hielscher, T., et al.**: Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. *J Clin Oncol*, 2013, 31, s. 4325–4332.
- 5 **Khan, R. – Dhodapkar, M. – Rosenthal, A., et al.**: Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). *Haematologica*, 2015, 100, s. 1214–1221.
- 6 **Yadav, P. – Sathick, I. J. – Leung, N., et al.**: Serum free light chain level at diagnosis in myeloma cast nephropathy – a multicentre study. *Blood Cancer J*, 2020, 10, s. 28.
- 7 **Hutchison, C. A. – Batuman, V. – Behrens, J., et al.**: The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. *Nat Rev Nephrol*, 2012, 8, s. 43–51.
- 8 **Adam, Z. – Starý, K. – Kubinyi, J., et al.**: Hyperkalcemie, příznaky, diferenciální diagnostika a léčba aneb důležitost vyšetřování kalcia. *Vnitř Lek*, 2016, 62, s. 370–383.